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levels, suggesting that most melanomas
lost E-cadherin expression and that multi-
ple paths to E-cadherin deregulation exist.
We still do not fully understand all of
the molecular steps required for onco-
genic BRAF to transform melanocytes
fully. Although the introduction of BRAF
V600E into primary human melanocytes
in vitro is associated with an initial burst
of replication, these effects are short-lived
and the cells eventually show signs of
oncogene-induced senescence. A number
of prior studies have suggested that Tbx3
(and the closely related Tbx2) promotes
oncogenesis, partly through the suppres-
sion of senescence. Despite this, and the
possibility that Tbx3 may limit the senes-
cence response in melanocytes, Boyd
et al. (2013) observed oncogenic BRAF
to induce senescence even when Tbx3
expression was increased. These results
add further weight to the emerging idea
that activity in multiple signaling path-
ways may be required to fully drive
melanocyte transformation. Although
Boyd et al. (2013) suggested a role for
p16INK4A in this process, other recent
studies have implicated increased PI3K/
AKT signaling, arising through either
PTEN loss or increased AKT3 expression,
in the escape of melanocytes from BRAF-
mediated senescence (Vredeveld et al.,
2012). It is further likely that the PI3K/AKT
signaling required for the escape from
BRAF-mediated senescence may also
enhance the EMT-like response of mela-
noma cells, leading to further potentiation
of environmental escape (Kalluri and
Weinberg, 2009). Insights into the poten-
tial cooperation between BRAF and the
PI3K/AKT signaling pathways in driving
the EMT-like response of melanoma cells
are likely to prove useful in our under-
standing of the earliest stages of
melanoma development.
The identification of mutant BRAF as a
bona fide therapeutic target in 50% of
melanoma patients and the subsequent
clinical development of small-molecule
BRAF inhibitors may revolutionize the
treatment of disseminated melanoma
(Fedorenko et al., 2011). The findings of
Boyd et al. (2013), as well as of others,
showing that BRAF inhibition reverses
partially the EMT-like state of mela-
noma, could represent a potential mecha-
nism through which BRAF inhibitors such
as vemurafenib and dabrafenib exert their
effects. It is also intriguing that Tbx3,
whose knockdown has multiple effects
on melanoma cells, including the reduc-
tion of anchorage-independent growth
and the abrogation of xenograft forma-
tion in immunocompromised mice, is
suppressed by BRAF inhibitors (Peres
et al., 2010). We are only now begin-
ning to understand how the acquisition of
driver mutations, such as mutant BRAF,
serve to rewire the signaling of melano-
cytes and drive them toward oncogenic
transformation. These insights, linking
mutant BRAF to E-cadherin and Tbx3,
provide important clues about how mela-
noma may be managed therapeutically.
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MicroRNAs as an Emerging Target
for Melanoma Therapy
Byungwoo Ryu1, Soonyean Hwang1 and Rhoda M. Alani1
Despite the growing focus on microRNAs (miRNAs) as novel diagnostic tools and
therapeutic targets in cancer, global characterization of miRNA expression patterns
and their specific targets in melanoma has lagged. In this issue, Reuland et al. (2013)
identify miR-26a as being specifically downregulated in human melanoma cells.
They further establish Silencer of Death Domains as a novel target for miR-26a,
which functionally mediates melanoma cell death. These findings suggest that
miR-26a may serve as a promising novel therapy for subsets of melanoma.
Journal of Investigative Dermatology (2013) 133, 1137–1139. doi:10.1038/jid.2012.505
MicroRNAs (miRNAs) are small non-
coding RNAs that regulate gene expres-
sion at the posttranscriptional level.
Precursor miRNAs are initially tran-
scribed in the nucleus and subsequently
cleaved by RNAse III into mature miR-
NAs. Once in the cytoplasm, these
molecules form an miRNA-induced
silencing complex that binds to the 30
untranslated regions of target transcripts.
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Deregulated miRNA expression has
been linked to human cancers; subse-
quently, numerous studies over the past
decade have sought to characterize
tumor-specific miRNA fingerprints in
various malignancies. Tumors of varying
subtypes exhibit unique miRNA expres-
sion patterns; furthermore, miRNAs are
highly stable molecules that may be
detected easily in circulating blood
(Mitchell et al., 2008). Thus, miRNAs
are viewed as potential biomarkers
for early tumor detection and for moni-
toring tumor burden. In addition, recent
studies have identified specific tumor-
associated functions attributable to a
variety of miRNAs, which in turn allow
them to be classified as potential onco-
genes or tumor suppressor genes (Calin
and Croce, 2006). Although targeting
of such miRNAs has been proposed as
a potential therapeutic approach in
treating cancer, it is notable that
miRNAs have been shown to bind
target transcripts with imperfect comple-
mentation and that they demonstrate
variable target gene promiscuity. Thus,
a single miRNA may regulate the
expression of several genes, which
may confound the functional utility of
therapies that target specific miRNAs.
Functional characterization of miRNAs
associated with melanoma progression
Although previous studies have sought
to characterize miRNA expression pro-
files in human melanomas (Zhang et al.,
2006), the first detailed comparison of
miRnomes between normal human mel-
anocytes and melanoma cell lines
derived from primary and metastatic
tumors was only recently reported by
Mueller et al., 2009. This study identi-
fied several alterations in the expression
of miRNAs associated with melanoma
progression and metastasis. Subsequent
studies also identified miRNAs associa-
ted with melanoma progression and the
metastatic phenotype; however, little
consensus has emerged with respect to
specific miRNA alterations in human
melanomas. Several miRNAs, including
miR-137, miR-148, and miR-182, have
been shown to regulate the micro-
phthalmia-associated transcription factor,
an oncogene in some melanomas.
These miRNAs have also been shown
to be regulated in melanoma cell lines,
and they may be associated with mela-
noma development and progression
(Bemis et al., 2008; Haflidadottir et al.,
2010; Segura et al., 2009). More
recently, miRNAs have been implica-
ted in the development of melanoma
drug resistance and organ-specific
metastasis (Liu et al., 2012). Despite
mounting data linking miRNAs to mela-
nomagenesis, few melanoma-associated
miRNAs have as yet been characterized
in depth. In this issue of the Journal
of Investigative Dermatology, Reuland
et al. (2013) provide important new
insights into miRNAs involved in
melanoma progression and their poten-
tial therapeutic utility. Through a micro-
array screen of miRNAs associated with
melanoma cell lines versus primary
melanocytes, the authors identify miR-
26a as being significantly downregu-
lated during melanoma development.
They further identify a functionally sig-
nificant role for miR-26a in promoting
apoptosis in human melanoma cells;
transfection experiments demonstrated
significant induction of programmed cell
death in the majority of human mela-
noma cell lines tested with miR-26a.
Exploration of known or putative down-
stream effectors of miR-26a confirmed
SMAD1 and silencer of death domains
(SODDs) as downstream effectors of the
apoptotic phenotype in miR-26a-sensi-
tive cell lines. Moreover, SODD was
found to have a functionally significant
role in mediating protection of mela-
noma cells from apoptotic mechanisms.
Characterization of miRNA-26a as a
critical regulator of a cell death pathway
Although miRNA-26a deregulation has
been implicated in various cancer types,
the function of decreased miR-26a in
melanoma progression had not been
well characterized. In the current manu-
script from Reuland et al. (2013), trans-
fection of miR-26a mimics in multiple
melanoma cell lines resulted in
increased cell death, which did not
occur in primary melanocytes. Among
the known targets of miR-26a, only
SMAD1 exhibited a consistent repres-
sion at the translational level during
miR-26a mimic treatment of melanoma
cell lines. However, knocking down
SMAD1 in the melanoma cell lines did
not result in the increased cell death that
was observed with miR-26a mimic treat-
ment, suggesting an alternative mediator
of these miR-26a effects. The authors
thus sought additional miR-26a targets.
They then identified SODD as a poten-
tial novel miR-26a effector (Figure 1) via
the TargetScan database through con-
sensus analysis of a putative miR-26a-
binding site in the 30 untranslated
regions of the SODD transcript. SODD
is a member of the BAG1 (BCL-2-asso-
ciated Athano-Gene 1) family, which is
involved in the regulation of apoptotic
cellular pathways (Antoku et al., 2001).
SODD has been shown to bind the
death domains of the tumor necrosis
factor receptor-1, which inhibits multi-
merization and activation in the
absence of ligand binding, thereby inhi-
bitng apoptosis (Antoku et al., 2001). In
the current study by Reuland et. al.
(2013), miR-26a inhibition and mimic
treatment validated SODD as a bona
fide miR-26a target with predicted
changes seen in SODD protein expres-
sion after manipulation of miR-26a,
whereas transcriptional regulation by
miR-26a was validated using a SODD
30 untranslated regions luciferase reporter
assay. Notably, Reuland et al. (2013)
found that SODD small interfering RNA
resulted in increased cell death within
miR-26a mimic–sensitive melanoma cell
lines, whereas knockdown of SMAD1
Clinical Implications
 miR-26a regulates the expression of silencer of death domains and
apoptotic mechanisms in human melanomas.
 miR-26a ‘‘treatment’’ of melanomas results in increased cell death through
targeted mechanisms.
 The use of miRNAs as potential therapies for melanoma may revolutionize
the treatment of melanomas, either as single-agent therapies or as
adjuvants that enhance other therapies.
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concurrently with SODD did not result
in an additive effect. These results were
reproduced in several melanoma cell
lines regardless of p53 mutational status,
suggesting a p53-independent apoptotic
mechanism. Citing the putative roles of
SODDs in decreasing tumor necrosis
factor-a-induced cell death and activat-
ing NFkB, the authors conclude that
SODD deregulation may be sufficient
to inhibit cell death in a subset of
melanomas and that SODD is a poten-
tial target for melanoma treatment
through activation of miR-26a.
miR-26a as a potential therapy
With the advancement of short RNA
delivery methods, miRNA replacement
therapies with mimics or suppression of
oncogenic miRNAs using designer
miRNA inhibitors look promising as
cancer therapies. The current work by
Reuland et al. (2013) provides addi-
tional optimism for such therapies
in melanoma. In particular, one may
speculate that such therapies could
enhance current immunotherapy
strategies for melanoma, which have
been proposed to be limited through
adaptive resistance to T cell–mediated
death pathways associated with the
downregulation of tumor necrosis factor–
related apoptosis-inducing ligand receptors
in targeted melanoma cells. miR-26a-
based therapies may provide a by-
pass mechanisms for such resistance
pathways and enhance immunotherapy
responses. Alternatively, apoptotic
mechanisms associated with targeted
therapies such as MAP kinase inhibitors,
or more traditional chemotherapeutic
agents or radiotherapies, might be speci-
fically enhanced through miR-26a treat-
ment. Clearly, additional studies on the
potential mechanism of miR-26a effects
in melanoma and potential synergies
with other therapies are needed.
The potential use of miRNA therapies
for melanoma suggests an attractive
and novel therapeutic opportunity for
this aggressive malignancy and hope
for future success for such therapeutic
modalities, either as singular agents
in the melanoma armamentarium or
combination therapies to enhance
other treatment modalities. The work
by Reuland et al. (2013) presents an
important new pathway for potential
therapeutic targeting in melanoma and
an exciting opportunity for the field.
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Figure 1. MicroRNA-26a regulation of silencer of death domain (SODD) and apoptosis in melanoma.
SODD regulation of melanoma programmed cell death is mediated by three molecular pathways:
(1) silencing of SODD by miR-26a may promote tumor necrosis factor (TNF)-induced apoptotic pathways
through activation of the TNF receptor-1 (TNF-R1) signaling pathway; (2) miR-26a may prevent the
formation of stable complexes of SODD, Hsp70, and Bcl-2, resulting in decreased levels of the
antiapoptotic protein Bcl-2; (3) SODD silencing may destabilize NF-kB complexes that have a pivotal
role in the TNF-R1 proapoptotic pathway. BAG, BCL-2-associated Athano-Gene 1.
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